Professor and Division Chief, Medical Laboratory Sciences, Department of Pathology, School of Medicine
Co-Director, Graduate Program in Laboratory Medicine and Biomedical Science
Associate Director, Center for Human Toxicology
Adjunct Professor, Department of Pharmacology and Toxicology
B.S., 1985, University of Utah, Medical Technology
M.S., 1988, University of Utah, Medical Laboratory Science
Ph.D., 1991, University of Utah. Health
Diana G. Wilkins is currently a Professor and Division Chief for Medical Laboratory Sciences in the Department of Pathology, University of Utah School of Medicine. She also concurrently holds positions as Associate Director of the Center for Human Toxicology and Adjunct Professor in the Department of Pharmacology and Toxicology, College of Pharmacy at the University of Utah. Previously, Dr. Wilkins served as an Assistant Director, the Quality Control /Quality Assurance Manager and Senior Toxicologist at the Center for Human Toxicology.
She received a B.S. (1985), M.S. (1988) and PhD. (1991) from the University of Utah. Her education included training in toxicology and pharmacology, with particular emphasis on drugs of abuse. She is a Laboratory Inspector for the National Laboratory Certification Program (NLCP) under the auspices of the Department of Health and Human Services (NIDA) and previously served as a Laboratory Assessor for the Standards Council of Canada (SCC).
Dr. Wilkins was a member of the Drug Testing Advisory Board (DTAB) of the Division of Workplace Performance, Department of Health and Human Services from 1994-1997. She has also served as an Ad Hoc member of several NIDA study sections and is currently a member of the Clinical Chemistry and Toxicology Devices Panel of the Food and Drug Administratio.
Dr. Wilkins participates in teaching undergraduate and graduate courses in laboratory management, clinical and analytical toxicology, pharmacology and statistics for at the University.
Her research interests include:
Dr. Wilkins belongs to several scientific associations including the American Academy of Forensic Sciences, the Society of Forensic Toxicology, the International Association of Forensic Toxicologists, the American Society for Clinical Laboratory Science, and the American Society of Clinical Pathologists.
Curry SC, Padilla-Jones A, O'Connor AD, Ruha AM, Bikin DS, Wilkins DG, Rollins DE, Slawson MH, Gerkin RD; Acetaminophen Adduct Study Group. (2014). Prolonged Acetaminophen-Protein Adduct Elimination During Renal Failure, Lack of Adduct Removal by Hemodiafiltration, and Urinary Adduct Concentrations After Acetaminophen Overdose. J Med Toxicol. 2014 Oct 7. [Epub ahead of print]
Munger MA, Hadlock G, Stoddard G, Slawson MH, Wilkins DG, Cox N, Rollins DE (2014). Characterization of orally doses silver nanoparticles on cytochrome P450 enzyme activity using multiple-probe technique. Nanotoxicology , Aug 19:1-8.
Anderson DJ., Brozek EM, Porucznik CA. Wilkins DG (2014). Biomonitoring method for bisphenol A in human urine by ultra-high performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci, 15;953-954:53-61.
Goldberger B, Wilkins D. (2013). Chapter 32: Analytical/Forensic Toxicology. In Klaassen C (Ed.), Casarett and Doull’s Toxicology: The Basic Science of Poisons (8th).
McGill MR, Lebofsky M, Norris HR, Slawson MH, Bajt ML, Xie Y, Williams CD, Wilkins DG, Rollins DE, Jaeschke H. (2013). Plasma and liver acetaminophen-protein adduct levels in mice after acetaminophen treatment: dose-response, mechanisms, and clinical implications. Toxicol Appl Pharmacol, 269(3), 240-9.
Vieira-Brock PL, Andrenyak DM, Nielsen SM, Fleckenstein AE, Wilkins DG. (2013). Age-Related Differences in the Disposition of Nicotine and Metabolites in Rat Brain and Plasma. Nicotine Tob Res. Nov;15(11):1839-48.
Himes SK, Goodwin RS, Rock CM, Jones HE, Johnson RE, Wilkins DG, Huestis MA. (2012). Methadone and metabolites in hair of methadone-assisted pregnant women and their infants. Ther Drug Monit, 34(3), 337-44.
Methamphetamine self-administration acutely decreases monoaminergic transporter function. Synapse, 66(3), 240-5.
McFadden LM, Stout KA, Vieira-Brock PL, Allen SC, Nielsen SM, Wilkins DG, Hanson GR, Fleckenstein AE. (2012).
McFadden LM, Hadlock GC, Allen SC, Vieira-Brock PL, Stout KA, Ellis JD, Hoonakker AJ, Andrenyak DM, Nielsen SM, Wilkins DG, Hanson GR, Fleckenstein AE. (2012). Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure. J Pharmacol Exp Ther, 340(2), 295-303.
Boileau I, Payer D, Houle S, Behzadi A, Rusjan PM, Tong J, Wilkins D, Selby P, George TP, Zack M, Furukawa Y, McCluskey T, Wilson AA, Kish SJ. (2012). Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study. J Neurosci (online), 32(4), 1353-9.
Vieira-Brock PL, Miller EI, Nielsen SM, Fleckenstein AE, Wilkins DG. (2011). Simultaneous quantification of nicotine and metabolites in rat brain by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci, 879(30), 3465-74
Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC, Andrenyak DM, Vieira-Brock PL, German CL, Conrad KM, Hoonakker AJ, Gibb JW, Wilkins DG, Hanson GR, Fleckenstein AE. (2011). 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther, 339(2), 530-6.
McFadden LM, Hoonakker AJ, Vieira-Brock PL, Stout KA, Sawada NM, Ellis JD, Allen SC, Walters ET, Nielsen SM, Gibb JW, Alburges ME, Wilkins DG, Hanson GR, Fleckenstein AE. (2011). Methamphetamine treatment during development attenuates the dopaminergic deficits caused by subsequent high-dose methamphetamine administration. Synapse, 65(8), 771-7.
Miller EI, Murray GJ, Rollins DE, Tiffany ST, Wilkins DG. (2011). Validation of a liquid chromatography-tandem mass spectrometry method for the detection of nicotine biomarkers in hair and an evaluation of wash procedures for removal of environmental nicotine. J Anal Toxicol, 35(6), 321-32.
Miller EI, Norris HR, Rollins DE, Tiffany ST, Moore CM, Vincent MJ, Agrawal A, Wilkins DG. (2010). Identification and quantification of nicotine biomarkers in human oral fluid from individuals receiving low-dose transdermal nicotine: a preliminary study. J Anal Toxicol, 34(7), 357-66.
Boileau I, Houle S, Rusjan PM, Furukawa Y, Wilkins D, Tong J, Selby P, Wilson AA, Kish SJ. (2010). Influence of a low dose of amphetamine on vesicular monoamine transporter binding: a PET (+)[11C]DTBZ study in humans. Synapse, 64(6), 417-20.
Kish SJ, Lerch J, Furukawa Y, Tong J, McCluskey T, Wilkins D, Houle S, Meyer J, Mundo E, Wilson AA, Rusjan PM, Saint-Cyr JA, Guttman M, Collins DL, Shapiro C, Warsh JJ, Boileau I. (2010). Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study. Brain, 133(Pt 6), 1779-97.
Miller EI, Norris HR, Rollins DE, Tiffany ST, Wilkins DG. (2010). A novel validated procedure for the determination of nicotine, eight nicotine metabolites and two minor tobacco alkaloids in human plasma or urine by solid-phase extraction coupled with liquid chromatography-electrospray ionization-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci, 878(9-10), 725-37.
Hadlock GC, Baucum AJ 2nd, King JL, Horner KA, Cook GA, Gibb JW, Wilkins DG, Hanson GR, Fleckenstein AE. (2009). Mechanisms underlying methamphetamine-induced dopamine transporter complex formation. J Pharmacol Exp Ther, 329(1), 169-74.